Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Privia Health (PRVA) Shares Outstanding (Weighted Average) (2020 - 2026)

Privia Health has reported Shares Outstanding (Weighted Average) over the past 6 years, most recently at $122.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 2.32% year-over-year to $122.2 million; the TTM value through Dec 2025 reached $122.2 million, up 2.32%, while the annual FY2025 figure was $122.2 million, 2.32% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $122.2 million at Privia Health, roughly flat from $122.8 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $122.8 million in Q3 2025 and troughed at $96.0 million in Q1 2021.
  • A 5-year average of $113.5 million and a median of $116.2 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): grew 0.06% in 2021 and later increased 12.58% in 2022.
  • Year by year, Shares Outstanding (Weighted Average) stood at $103.0 million in 2021, then grew by 7.52% to $110.7 million in 2022, then increased by 5.45% to $116.7 million in 2023, then rose by 2.29% to $119.4 million in 2024, then increased by 2.32% to $122.2 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for PRVA at $122.2 million in Q4 2025, $122.8 million in Q3 2025, and $122.1 million in Q2 2025.